TRTMNT W/LAMIVUDINE+STAVUDINE+ABACAVIR+AMPRENAVIR/RITONAVIR W/SUPV INTERRUPTION

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这项研究的目的是观察是否使用五种抗？在HIV感染的早期阶段，HIV药物可以使血液和某些身体组织中的HIV病毒无法检测到，即使停止服用这些药物，病毒是否仍然无法检测到。本研究将使用拉米夫定（3TC, Epivir¿），司他夫定（d4T, Zerit¿），阿巴卡韦（ABC, 1592U89, Ziagen¿），利托那韦（RTV, Norvir¿）和安普雷那韦（APV, 141W94, Agenerase¿）。也可以使用二磷酸腺苷（ddI, Videx¿）和奈非那韦（NFV, viraccept¿）。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is designed to see if using a combination of five anti?HIV drugs during the early stage of HIV infection can make the HIV virus in the blood and in certain body tissues undetectable, and whether the virus will stay undetectable even after you stop taking these drugs. This study will use lamivudine (3TC, Epivir¿), stavudine (d4T, Zerit¿), abacavir (ABC, 1592U89, Ziagen¿), ritonavir (RTV, Norvir¿), and amprenavir (APV, 141W94, Agenerase¿). Didanosine (ddI, Videx¿) and nelfinavir (NFV, Viracept¿) may also be used.